Article
The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.
Lung cancer (Amsterdam, Netherlands) - 1 Jun 2008
Riely Gregory J
Abstract excerpt
Initial studies with the first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib in patients with non-small cell lung cancer (NSCLC) showed that, although most did not have an objective radiographic response, a minority of patients had dramatic and durable clinical and radiographic responses. The discovery of EGFR mutations in tumours from patients with NSCLC...
Topics
- Carcinoma, Non-Small-Cell Lung
- Drug Resistance, Neoplasm
- ErbB Receptors
- Erlotinib Hydrochloride
- Gefitinib
- Humans
- Lung Neoplasms
- Mutation
- Protein Kinase Inhibitors
- Quinazolines